Kamada's Plans For Emphysema Drug Delayed By Years After MAA Withdrawal
Executive Summary
Kamada has withdrawn its European approval application for an inhaled version of its emphysema drug Glassia – a move that shocked investors because of the company's continued insistence data from a failed pivotal study would be enough to convince regulators.